Aligos Therapeutics Future Growth
Future criteria checks 2/6
Aligos Therapeutics is forecast to grow earnings and revenue by 6.6% and 80.4% per annum respectively while EPS is expected to grow by 15.8% per annum.
Key information
6.6%
Earnings growth rate
15.8%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | 80.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 06 Jun 2024 |
Recent future growth updates
Recent updates
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues
May 24
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -145 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -120 | N/A | N/A | 1 |
| 12/31/2024 | 1 | -114 | N/A | N/A | 1 |
| 3/31/2024 | 14 | -100 | -79 | -79 | N/A |
| 12/31/2023 | 16 | -88 | -79 | -79 | N/A |
| 9/30/2023 | 16 | -82 | -73 | -73 | N/A |
| 6/30/2023 | 17 | -82 | -70 | -70 | N/A |
| 3/31/2023 | 14 | -83 | -82 | -81 | N/A |
| 12/31/2022 | 14 | -96 | -80 | -79 | N/A |
| 9/30/2022 | 11 | -112 | -101 | -100 | N/A |
| 6/30/2022 | 8 | -126 | -110 | -108 | N/A |
| 3/31/2022 | 6 | -136 | -107 | -106 | N/A |
| 12/31/2021 | 4 | -128 | -117 | -116 | N/A |
| 9/30/2021 | 4 | -125 | -98 | -98 | N/A |
| 6/30/2021 | 2 | -125 | -90 | -89 | N/A |
| 3/31/2021 | 1 | -116 | -85 | -84 | N/A |
| 12/31/2020 | N/A | -109 | -76 | -74 | N/A |
| 9/30/2020 | N/A | -92 | -72 | -70 | N/A |
| 6/30/2020 | N/A | -73 | -69 | -66 | N/A |
| 3/31/2020 | N/A | -62 | -61 | -58 | N/A |
| 12/31/2019 | N/A | -52 | -50 | -47 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALGS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALGS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALGS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALGS's revenue (80.4% per year) is forecast to grow faster than the US market (8.5% per year).
High Growth Revenue: ALGS's revenue (80.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALGS's Return on Equity is forecast to be high in 3 years time